JWK-008 is under clinical development by Chengdu Genevector Biotechnology and currently in Phase I for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). According to GlobalData, Phase I drugs for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JWK-008 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JWK-008 is under development for the treatment of mucopolysaccharidosis I (MPS I). The therapeutic candidate comprises adeno-associated viral (AAV) vector delivering alpha L-iduronidase (IDUA). The drug candidate is administered through intravenous route.
Chengdu Genevector Biotechnology overview
Chengdu Genevector Biotechnology (Genevector) is a healthcare service provider which provides gene therapy solutions for multiple diseases. Genevector is headquartered in Chengdu, Sichuan, China.
For a complete picture of JWK-008’s drug-specific PTSR and LoA scores, buy the report here.